BrightView (NYSE:BV) Announces Earnings Results

BrightView (NYSE:BV) released its quarterly earnings results on Tuesday. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.12), FiscalAI reports. BrightView had a net margin of 0.74% and a return on equity of 5.00%. The business had revenue of $717.60 million during the quarter, compared to the consensus estimate of $726.13 million. The business’s quarterly revenue was up 1.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.30 earnings per share.

BrightView Trading Up 4.9%

BV stock traded up $0.52 during midday trading on Thursday, hitting $11.12. 1,068,056 shares of the company’s stock were exchanged, compared to its average volume of 708,350. BrightView has a one year low of $10.42 and a one year high of $15.82. The stock’s fifty day moving average price is $13.50 and its 200-day moving average price is $12.96. The company has a market cap of $1.04 billion, a PE ratio of -44.74 and a beta of 1.18. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.23 and a current ratio of 1.23.

Wall Street Analyst Weigh In

BV has been the topic of a number of research reports. BTIG Research reiterated a “buy” rating and set a $16.00 target price on shares of BrightView in a research report on Monday, May 11th. Morgan Stanley decreased their price objective on BrightView from $14.00 to $12.50 and set an “equal weight” rating on the stock in a research report on Thursday. Zacks Research downgraded BrightView from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. Weiss Ratings reiterated a “sell (d+)” rating on shares of BrightView in a research report on Friday, July 31st. Finally, Oppenheimer assumed coverage on shares of BrightView in a research report on Wednesday, June 17th. They set an “outperform” rating and a $17.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, two have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, BrightView presently has a consensus rating of “Hold” and a consensus price target of $14.10.

Hedge Funds Weigh In On BrightView

Institutional investors and hedge funds have recently modified their holdings of the business. Jump Financial LLC bought a new stake in shares of BrightView in the fourth quarter valued at about $235,000. Intech Investment Management LLC boosted its position in BrightView by 14.4% during the 4th quarter. Intech Investment Management LLC now owns 28,497 shares of the company’s stock worth $361,000 after acquiring an additional 3,589 shares during the last quarter. Brevan Howard Capital Management LP grew its stake in shares of BrightView by 44.3% during the 3rd quarter. Brevan Howard Capital Management LP now owns 20,779 shares of the company’s stock worth $278,000 after acquiring an additional 6,384 shares in the last quarter. Occudo Quantitative Strategies LP bought a new position in shares of BrightView during the 3rd quarter worth approximately $352,000. Finally, Brown Brothers Harriman & Co. bought a new stake in shares of BrightView in the third quarter worth $351,000. 92.41% of the stock is currently owned by institutional investors and hedge funds.

BrightView Company Profile

BrightView Inc (NYSE:BV) is a leading commercial landscaping services company in the United States, offering a comprehensive suite of outdoor asset management solutions. The company’s core business activities include landscape maintenance, development and enhancement services tailored to a wide array of clients such as corporate campuses, healthcare facilities, multi-family residential properties, retail centers and municipalities.

BrightView’s service portfolio covers routine grounds maintenance, landscape construction and design-build, irrigation system installation and management, tree care, seasonal color programs and snow and ice management.